Chelatec is very pleased to see this article published regarding the preclinical and clinical development of [211At]At-anti-CA-IX, an alpha-emitter-labeled antibody developed by ATONCO that shows great promise in the treatment of bladder cancer. Chelatec as a service provider has largely contributed to the preclinical phase (in vitro and in vivo) under the responsibility of Gaelle Gautier, Preclinical Manager at Chelatec.
Read the full article here: https://www.mdpi.com/3250554